Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to test:

1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D
B: Arm Label: Group 1 (favorable prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 2 (intermediate prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 3 (poor prognosis); Type: EXPERIMENTAL; Interventions: Drug: carmustine, Drug: cisplatin, Drug: cytarabine, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: gemcitabine hydrochloride, Drug: ifosfamide, Drug: melphalan, Drug: methylprednisolone, Drug: mitoguazone, Drug: vindesine, Drug: vinorelbine tartrate, Procedure: allogeneic hematopoietic stem cell transplantation, Procedure: autologous hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: mitoguazone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: allogeneic hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis)
C: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine sulfate | Arm Label: BEACOPP-14 chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Arm Label: BEACOPP-escalated chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisolone, Drug: procarbazine hydrochloride, Drug: vincristine sulfate | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm I, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I, Arm II, BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: procarbazine hydrochloride; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy | Intervention Type: DRUG; Name: vinblastine sulfate; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): BEACOPP-14 chemotherapy, BEACOPP-escalated chemotherapy
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: BEACOPP escalated | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: BEACOPP escalated; Assigned to Arm(s): A, B, C, D

Answer: D